dc.contributor.author | DeRosa, Frank | |
dc.contributor.author | Langer, Robert | |
dc.contributor.author | Kauffman, Kevin John | |
dc.contributor.author | McClellan, Rebecca L | |
dc.contributor.author | Appel, Eric | |
dc.contributor.author | Dorkin, Joseph Robert | |
dc.contributor.author | Tibbitt, Mark W | |
dc.contributor.author | Langer, Robert S | |
dc.contributor.author | Anderson, Daniel Griffith | |
dc.contributor.author | Fenton, Owen Shea | |
dc.date.accessioned | 2017-02-10T15:50:07Z | |
dc.date.available | 2017-02-10T15:50:07Z | |
dc.date.issued | 2016-02 | |
dc.date.submitted | 2016-01 | |
dc.identifier.issn | 0935-9648 | |
dc.identifier.issn | 1521-4095 | |
dc.identifier.uri | http://hdl.handle.net/1721.1/106890 | |
dc.description.abstract | Thousands of human diseases could be treated by selectively controlling the expression of specific proteins in vivo. A new series of alkenyl amino alcohol (AAA) ionizable lipid nanoparticles (LNPs) capable of delivering human mRNA with unprecedented levels of in vivo efficacy is demonstrated. This study highlights the importance of utilizing synthesis tools in tandem with biological inspiration to understand and improve nucleic acid delivery in vivo. | en_US |
dc.description.sponsorship | National Science Foundation (U.S.). Graduate Research Fellowship Program | en_US |
dc.description.sponsorship | Shire Pharmaceuticals | en_US |
dc.description.sponsorship | Wellcome Trust-MIT Postdoctoral Fellowship | en_US |
dc.language.iso | en_US | |
dc.publisher | Wiley Blackwell | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1002/adma.201505822 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
dc.source | PMC | en_US |
dc.title | Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Fenton, Owen S. et al. “Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery.” Advanced Materials 28.15 (2016): 2939–2943. | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Institute for Medical Engineering & Science | en_US |
dc.contributor.department | Harvard University--MIT Division of Health Sciences and Technology | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemical Engineering | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Chemistry | en_US |
dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
dc.contributor.mitauthor | Fenton, Owen S. | |
dc.contributor.mitauthor | Kauffman, Kevin John | |
dc.contributor.mitauthor | McClellan, Rebecca L | |
dc.contributor.mitauthor | Appel, Eric | |
dc.contributor.mitauthor | Dorkin, Joseph Robert | |
dc.contributor.mitauthor | Tibbitt, Mark W | |
dc.contributor.mitauthor | Langer, Robert S | |
dc.contributor.mitauthor | Anderson, Daniel Griffith | |
dc.relation.journal | Advanced Materials | en_US |
dc.eprint.version | Author's final manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
dspace.orderedauthors | Fenton, Owen S.; Kauffman, Kevin J.; McClellan, Rebecca L.; Appel, Eric A.; Dorkin, J. Robert; Tibbitt, Mark W.; Heartlein, Michael W.; DeRosa, Frank; Langer, Robert; Anderson, Daniel G. | en_US |
dspace.embargo.terms | N | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-5585-9280 | |
dc.identifier.orcid | https://orcid.org/0000-0002-9436-2453 | |
dc.identifier.orcid | https://orcid.org/0000-0002-2301-7126 | |
dc.identifier.orcid | https://orcid.org/0000-0002-4917-7187 | |
dc.identifier.orcid | https://orcid.org/0000-0003-4255-0492 | |
dc.identifier.orcid | https://orcid.org/0000-0001-5629-4798 | |
mit.license | OPEN_ACCESS_POLICY | en_US |